PREDICTION OF PLASMA CONCENTRATIONS FROM FIXED-DOSE COMBINATION FORMULATIONS: IBUPROFEN/PARACETAMOL DRUG PRODUCTS
DOI:
https://doi.org/10.22159/ajpcr.2025v18i7.54807Keywords:
Convolution, Ibuprofen, Mini-vessels method, Paracetamol, USP apparatus IVAbstract
Objectives: To predict the in vivo performance of ibuprofen and paracetamol (suspension and tablets) using dissolution data of mini-vessels, standard-vessels, United States Pharmacopeia (USP) apparatus IV, and a convolution approach.
Methods: The reference suspension was tested with mini-vessels (200 mL of dissolution medium), USP standard-vessels (900 mL at 75 rpm), and USP apparatus IV (laminar flow at 16 mL/min). The reference and a generic formulation (tablets) were tested with USP apparatus II and IV. Both drugs were quantified by an ultraviolet derivative method. Dissolution efficiency, mean dissolution time, t50%, and t80%of tablets were calculated and statistically compared (Student’s t-test). Predicted drug plasma concentrations were calculated. Hypothetical Cmax and area under the concentration-time curve from zero to infinity (AUC0-inf) were compared with real pharmacokinetic values through the calculation of prediction error (PE). PE values should not exceed 10%.
Results: Suspension released a range of 94.51–101.07% of ibuprofen and 94.96–101.28% of paracetamol at 60 min among different dissolution methods. Similar profiles between reference and generic tablets were found with the USP apparatus IV (f2=75.51 for ibuprofen and 79.07 for paracetamol). Significant differences were found with all dissolution parameters of the standard-vessels (*p<0.05). The PE values for Cmax of ibuprofen and paracetamol were 7.47 and –8.96%, and for AUC0-inf –0.16 and 0.29% from suspension using the mini-vessels and –1.17 and 1.11% for Cmax and –7.91 and –7.14% for AUC0-inf from reference tablets using the USP apparatus IV.
Conclusion: Better predictions were found with the mini-vessels method using dissolution data of suspension and the USP apparatus IV using data from tablets.
Downloads
References
Sánchez-Dengra B, González-García I, González-Álvarez M, González-Álvarez I, Bermejo M. Two-step in vitro-in vivo correlations: Deconvolution and convolution methods, which one gives the best predictability? Comparison with one-step approach. Eur J Pharm Biopharm. 2021;158:185-97. doi: 10.1016/j.ejpb.2020.11.009, PMID 33248267
Abdelfattah F, Taha N, Abdou A, Mursi N, Emara L. Prediction of in vivo performance of ibuprofen immediate-release products using different dissolution models. J Appl Pharm Sci. 2022;12(8):193-201. doi: 10.7324/JAPS.2022.120820
Medina-López JR, Leyva-Hernández JM, Hernández-Osornio JJ, Ruiz-Segura JC. Simulated acetaminophen plasma profiles from fixed-dose combination formulations: Studies using the flow-through cell dissolution method. Int J Res Pharm Sci. 2024;15(2):33-41. doi: 10.26452/ijrps.v15i2.4674
Scheubel E, Lindenberg M, Beyssac E, Cardot JM. Small volume dissolution testing as a powerful method during pharmaceutical development. Pharmaceutics. 2010;2(4):351-63. doi: 10.3390/ pharmaceutics2040351, PMID 27721362
Sowmya C, Abrar Ahmed H, Suriya Prakaash KK. Virtual bioequivalence in pharmaceuticals: Current status and future prospects. Int J App Pharm. 2023;15(5):1-9. doi: 10.22159/ijap.2023v15i5.48589
Godman B, McCabe H, Leong TD, Mueller D, Martin AP, Hoxha I. Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Rev Pharmacoecon Outcomes Res. 2020;20(1):1-26. doi: 10.1080/14737167.2020.1734456, PMID 32237953
Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, et al. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci. 2005;94(10):2121-31. doi: 10.1002/ jps.20444, PMID 16136567
Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, et al. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). J Pharm Sci. 2006;95(1):4-14. doi: 10.1002/jps.20477, PMID 16307451
Medina-López R, Lara-Veloz J, Reyes-Ramírez FD. Influence of dissolution vessel capacity for predicting hypothetical drug plasma concentrations. Lat Am J Pharm. 2025;44(4):386-95.
Acetaminophen tablets monograph. Ibuprofen tablets monograph. Acetaminophen oral suspension monograph. Ibuprofen oral suspension monograph. In United States Pharmacopeia USP 47/NF 42 United States Pharmacopeial Convention. Inc; Rockville MD; 2024.
FDA. Guidance for Industry: Waiver of in vivo Bioavailability and Bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutical Classification System. United States Department of Health and Human Services. Center for Drug Evaluation and Research (CDER); 2017.
COFEPRIS. Listado Actualizado de Medicamentos de Referencia, Mexico; 2024. Available from: https://www.gob.mx/cms/ uploads/attachment/file/945072/lmr_2024-02_actualizaci_n_06_ septiembre_2024.pdf [Last accessed on 2025 Apr 27].
Medina R, Cázares IS, Hurtado M, Domínguez-Ramírez AM. Estimation of acetaminophen and ibuprofen in tablets by a derivative UV method: Characterization of in vitro release using USP apparatuses 2 and 4. Lat Am J Pharm. 2017;36(4):706-15.
Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12(3):263-71. doi: 10.1208/s12248-010-9185- 1, PMID 20373062
Yuksel N, Kanik AE, Baykara T. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods. Int J Pharm. 2000;209(1-2):57-67. doi: 10.1016/S0378- 5173(00)00554-8, PMID 11084246
Cardot JM, Lukas JC, Muniz P. Time scaling for in vitro-in vivo correlation: The inverse release function (IRF) approach. AAPS J. 2018;20(6):95. doi: 10.1208/s12248-018-0250-5, PMID 30159772
Qureshi SA. In vitro-in vivo correlation (IVIVC) and determining drug concentrations in blood from dissolution testing - a simple and practical approach. Open Drug Deliv J. 2010;4(2):38-47. doi: 10.2174/1874126601004020038
Poveda Andrés JL, García Robles AA, Pérez Huertas P. Farmacología del ibuprofeno intravenoso. Rev Soc Esp Dolor. 2016;23(Suppl 1):3-12.
Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel. Comput Methods Programs Biomed. 2010;99(3):306-14. doi: 10.1016/j.cmpb.2010.01.007, PMID 20176408
Villalva-Rojas O, Grande-Ortíz M, Ortiz J, Isasi J, Yantas D, Fiestas V. Bioequivalence study of ibuprofen 400 mg tablets. Rev Peru Med Exp Salud Publ. 2007;24:356-62.
Farré M, Roset PN, Pascual JA, Hernández-López C, Mas M, Marcos J, et al. Study of the absorption rate and bioavailability of 650 mg Gelocatil tablets. Dolor Investig Clin Ter. 2001;16(1):27-32.
Bendas ER. Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride. Arch Pharm Res. 2009;32(9):1317-29. doi: 10.1007/s12272-009-1918-2, PMID 19784589
Ilango KB, Kavimani S. A systematic review of mathematical models of pharmaceutical dosage forms. Int J Curr Pharm Rev Res. 2015;6(1):59-70.
Medina JR, Cortes M, Romo E. Comparison of the USP apparatus 2 and 4 for testing the in vitro release performance of ibuprofen generic suspensions. Int J App Pharm. 2017;9(4):90-5. doi: 10.22159/ ijap.2017v9i4.19926
Emara LH, Abdelfattah FM, Taha N, El-Ashmawy AA, Mursi NM. In vitro evaluation of ibuprofen hot-melt extruded pellets employing different designs of the flow-through cell. Int J Pharm Pharm Sci. 2014;6(9):192-97.
Hamed S, Ayob FA, Alfatama M, Doolaanea AA. Enhancement of the immediate release of paracetamol from alginate beads. Int J App Pharm. 2017;9(2):47-51. doi: 10.22159/ijap.2017v9i2.15672
Medina-López JR, Ríos-López A, Reyes-Ramírez FD. Convolution approach to estimate the in vivo behavior of ibuprofen soft gelatin capsules from in vitro release data of USP apparatus 4. Int J Res Pharm Sci. 2024;15(4):88-94. doi: 10.26452/ijrps.v15i4.4727
Chen BK, Yang YT. Post-marketing surveillance of prescription drug safety: Past, present, and future. J Leg Med. 2013;34(2):193-213. doi: 10.1080/01947648.2013.800797, PMID 23980746
Neves EO, Sales PM, Silveira D. Post-marketing sampling and testing programs for licensed medicinal product: A narrative review. Braz J Pharm Sci. 2022;58:e19538. doi: 10.1590/s2175- 97902022e19538
Da Silva Honório T, Simon A, Machado RM, Rodrigues CR, Do Carmo FA, Cabral LM, et al. Use of in silico methodologies to predict the bioavailability of oral suspensions: A regulatory approach. Curr Pharm Des. 2023;29(38):3040-9. doi: 10.2174/011381612825702 8231030113156, PMID 37957861
Published
How to Cite
Issue
Section
Copyright (c) 2025 Jose Raul Medina-Lopez, Juan Carlos Ruiz-Segura
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
